A heterocyclic compound 1-propenyl-1,3-dihydro-benzimidazol-2-one was synthesized by a palladium-catalyzed rearrangement reaction. Anticancer activities were confirmed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against Neura 2a (neuroblastoma cell), HEK 293 (kidney cancer) and MCF-7 (breast cancer) cell lines at low micromolar range. Furthermore, clear images from phase-contrast and fluorescence microscopes and confocal images unambiguously confirm the cancer cell death. The single X-ray crystal structure of the compound unambiguously proves the structure of the benzimidazolone compound.
Keyphrases
- papillary thyroid
- cell death
- optical coherence tomography
- deep learning
- squamous cell
- convolutional neural network
- magnetic resonance
- single cell
- high throughput
- lymph node metastasis
- stem cells
- breast cancer cells
- young adults
- mass spectrometry
- cell proliferation
- quantum dots
- signaling pathway
- raman spectroscopy
- case control
- pi k akt